| Icoria, Inc. (NASDAQ:ICOR) , an integrated systems biology company, announced today that Thomas J. Colatsky, Ph.D., Icoria's Vice President, Healthcare Research, will be a panelist in a focus session entitled, "Biomarkers and Drugs: A Happy Marriage?" at the BIO CEO & Investor Conference on Wednesday, February 23, 2005 at 9:30 AM ET in the Conrad Suite at the Waldorf-Astoria in New York.
|
RESEARCH TRIANGLE PARK, N.C. -- Icoria, Inc. (NASDAQ:ICOR) , an integrated systems biology company, announced today that Thomas J. Colatsky, Ph.D., Icoria's Vice President, Healthcare Research, will be a panelist in a focus session entitled, "Biomarkers and Drugs: A Happy Marriage?" at the BIO CEO & Investor Conference on Wednesday, February 23, 2005 at 9:30 AM ET in the Conrad Suite at the Waldorf-Astoria in New York.
About Icoria
Icoria, Inc. is a biotech company dedicated to deciphering the complexity of biological processes through the application of systems biology to identify biomarkers for drug discovery and development, diagnostics and to develop novel agrichemicals. Icoria has major contracts with the National Institute of Environmental Health Sciences, the Monsanto Company and Pioneer Hi-Bred International (a subsidiary of DuPont). Icoria also has a major grant from the National Institute of Standards & Technology's Advanced Technology Program. For more information, visit http://www.icoria.com/ .
This press release contains forward-looking statements. Such forward- looking statements are based on management's current expectations and are subject to a number of risks, factors and uncertainties that may cause actual results, events and performance to differ materially from those referred to in the forward-looking statements. These risks, factors and uncertainties include, but are not limited to, Icoria's early stage of development, history of net losses, technological and product development uncertainties, reliance on research collaborations, uncertainty of additional funding and ability to protect its patents and proprietary rights. Certain of these and other risks are identified in Icoria's annual report on Form 10-K for the year ended December 31, 2003 and in its quarterly report on Form 10-Q for the quarter ended September 30, 2004, each filed with the Securities and Exchange Commission. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in our expectations, except as may be required by law.
Source: Icoria, Inc.
|